CTMX: CytomX Corp Year-over-year earnings per share growth for the last twelve months

Public company logo of CytomX Pharma (CTMX)

The CytomX Therapeutics (CTMX) ecosystem is based on strategic alliances with industry behemoths, where funding depends on clinical trial results. Large-scale alliances ensure a flow of royalties and antibody development payments. Management is focused on monetizing new targets through licensing. The GURU.Markets interface displays this chart, where the current quarterly EPS trend has reached a mark, and this indicator equals -6.10.

CytomX Pharma (CTMX) - Quarterly EPS earnings growth from 07/04/2022 to 11/14/2026

Analytical breakdowns for CytomX Corp (CTMX)

- market value and analyst target forecast:
Price Chart CytomX Therapeutics, Inc.|CTMX - Forecast Levels Chart
- market capitalization information:
Market Value CytomX Therapeutics Inc|CTMX - Total Company Value
- book capitalization data:
Book Value per Share CytomX Therapeutics|CTMX - Book Capitalization|Market Cap to Net Assets Ratio cytomx.com|CTMX - Aggregate Business Assets
- debt burden and liquidity indicators:
Total Debt to Capital CytomX Therapeutics|CTMX - Long-Term Liabilities to Equity|Short-Term Debt to Equity CytomX Therapeutics|CTMX - Company Cumulative Debt|Debt to Book Capitalization Ratio CytomX Therapeutics Inc|CTMX - Company Long-Term Loans and Borrowings|Company Short-Term Debt CytomX Therapeutics|Quick Liquidity cytomx.com
- earnings and valuation multiples indicators:
CTMX - Net Financial Result|Projected Future Earnings CytomX Therapeutics|CTMX - Price to Earnings Ratio|Projected Price to Earnings CytomX Therapeutics Inc|CTMX - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio CytomX Therapeutics Inc|CTMX - Company profit before taxes, interest and amortization|Earnings per share for the last twelve months CytomX Therapeutics|CTMX - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months cytomx.com|CTMX - Net earnings per share growth this year|Expected earnings per share growth for next year CytomX Therapeutics
- revenue and sales details:
CTMX - Company Sales Volume|Company Future Sales Volume CytomX Therapeutics, Inc.|CTMX - Market Capitalization-to-Revenue Ratio|Forward Price-to-Revenue Multiple CytomX Therapeutics Inc
Comprehensive company analysis:CytomX Therapeutics
Flagship merchandise of CytomX Therapeutics

CytomX Therapeutics (CTMX) revenues depend directly on the success of the Probody platform and payments from strategic partners. Quarterly EPS growth measures the dynamics of net profit per share, reflecting the efficiency of business scaling. This metric allows for the timely detection of a slowdown in profit growth, preventing an overvaluation of the asset. Investors must distinguish temporary peaks from a sustainable trend. Analyzing the current quarterly EPS rate helps objectively assess the company's fundamental value.

Who CytomX Therapeutics competes with

Geron (GERN) - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share trend for the last twelve months NBTX (Nanobiotix SA)|Year-over-year earnings per share growth for the last twelve months Bicycle Pharma|Year-over-year earnings per share growth for the last twelve months CATX|Quarterly EPS earnings growth GNLX|Quarterly EPS earnings growth Molecular Partners Ltd (MOLN)|Oncolytics Biotech - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months LSTA (Lisata Therapeutics Inc.)|Moleculin - Quarterly EPS earnings growth|Year-over-year net earnings per share trend for the last twelve months GRTX|Molecular Templates (MTEM) - Year-over-year earnings per share growth for the last twelve months